Chickenpox pneumonia: experience with antiviral treatment

R N DAVIDSON, W LYNN, P SAVAGE, M H WANSBROUGH-JONES

From the Department of Communicable Diseases and Radiology, St George's Hospital, London

ABSTRACT  Of 13 patients with chickenpox pneumonia (12 of them adults) treated during 1979–87, 10 received antiviral drugs—nine acyclovir and one vidarabine. Three died despite intensive treatment. Serious secondary infections occurred in six cases. There were no clear indications that antiviral treatment altered the natural history of the condition. Acyclovir may at present be used too late in the course of chickenpox pneumonia to alter its outcome.

Introduction

Chickenpox pneumonia, first described in 1942,1 can be severe or even fatal in previously healthy individuals.2–8 Estimates of its incidence vary, the highest being half of all adult cases of chickenpox.5 A study of United States military personnel found radiographic changes in 16% of adult patients, of whom only a third had symptoms.6 Other authors report an incidence of pneumonia of 16·5%3 and 14%1 of adult cases, with a far higher incidence in pregnant women.5 In children the incidence of pneumonia has ranged from 0·8% to 14%.9–10 Malignant disease and cytotoxic and steroid treatment are predisposing factors.11 Published case reports12–17 suggest that antiviral treatment is beneficial. The onset of respiratory symptoms, however, is often late and, as the efficacy of antiviral drugs for varicella-zoster virus infections is related to the time at which treatment is started, we may reasonably doubt whether antiviral drugs would be of benefit.

During 1985 five patients with chickenpox pneumonia in adults were seen by our regional communicable diseases unit. Review of the records showed that five cases had occurred in the previous six years, and since then two cases in 1986 and one in 1987. This experience has prompted a review of the clinical, laboratory, and radiological features of chickenpox pneumonia since antiviral treatment became available.

Address for reprint requests: Dr M H Wansbrough-Jones, Department of Communicable Diseases, St George's Hospital Medical School, London SW17 0RE.

Accepted 11 May 1988

Methods

The patients were admitted to the regional communicable disease unit at St George’s Hospital from 1979 to 1987. Most were referred from within Wandsworth Health District (population 290 000). The diagnosis of chickenpox was not in doubt clinically and in all patients either there was a contact history or varicella-zoster virus was identified directly (five patients) or on the basis of a significant rise in specific antibody titre. Case notes were reviewed to obtain information on clinical features, results of laboratory investigations, treatment, and outcome.

Results

Details of the patients are given in the table. Ten patients complained of cough or breathlessness and five produced small amounts of blood stained sputum. Five patients had chest pain and most had discomfort over the trachea. Vesicles were present on the palate of all patients and lesions were seen in the larynx and trachea during intubation of patient 6. In patients 7 and 9 respiratory symptoms preceded the appearance of a rash by a day, whereas the rash preceded respiratory symptoms by two to five days in the remaining patients. Signs of pneumonia were confined to tachypnoea and sparse fine inspiratory crackles at the lower zones.

Two patients may have had altered immunity. Patient 3 had received a bone marrow transplant two and a half years earlier for aplastic anaemia. She had been regarded as immunologically normal before her fatal illness and she was not receiving immuno-suppressive drugs. Sarcoidosis had been diagnosed
Timing of events, treatment, and outcome in 13 patients with chickenpox pneumonia

<table>
<thead>
<tr>
<th>Patient No</th>
<th>Age, sex</th>
<th>Smoker</th>
<th>Onset of respiratory symptoms (days after rash started)*</th>
<th>Antiviral treatment</th>
<th>Duration of rash (days) before drug started</th>
<th>Days in hospital</th>
<th>Days of IPPV</th>
<th>Outcome</th>
<th>Other conditions</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>37, M</td>
<td>Yes</td>
<td>?</td>
<td>ARA-A</td>
<td>?</td>
<td>9</td>
<td>0</td>
<td>R</td>
<td>Sarcoidosis</td>
</tr>
<tr>
<td>2</td>
<td>31, F</td>
<td>Yes</td>
<td>2</td>
<td>None</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>R</td>
<td>Multiple sclerosis</td>
</tr>
<tr>
<td>3</td>
<td>14, F</td>
<td>No</td>
<td>5</td>
<td>ACV</td>
<td>5</td>
<td>2</td>
<td>1</td>
<td>D</td>
<td>Bone marrow transplant</td>
</tr>
<tr>
<td>4</td>
<td>39, M</td>
<td>Yes</td>
<td>4</td>
<td>None</td>
<td>4</td>
<td>0</td>
<td>0</td>
<td>R</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>29, F</td>
<td>Yes</td>
<td>3</td>
<td>ACV</td>
<td>8</td>
<td>0</td>
<td>16</td>
<td>R</td>
<td>Encephalitis, hepatitis</td>
</tr>
<tr>
<td>6</td>
<td>47, M</td>
<td>Yes</td>
<td>3</td>
<td>ACV</td>
<td>3</td>
<td>2</td>
<td>1</td>
<td>D</td>
<td>Hepatitis B virus carriage</td>
</tr>
<tr>
<td>7</td>
<td>39, M</td>
<td>Yes</td>
<td>-1</td>
<td>ACV</td>
<td>16</td>
<td>0</td>
<td>11</td>
<td>R</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>27, M</td>
<td>Yes</td>
<td>2</td>
<td>ACV</td>
<td>23</td>
<td>5</td>
<td>16</td>
<td>R</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>36, F</td>
<td>No</td>
<td>-1</td>
<td>ACV</td>
<td>4</td>
<td>13</td>
<td>5</td>
<td>R</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>29, M</td>
<td>No</td>
<td>3</td>
<td>None</td>
<td>6</td>
<td>0</td>
<td>0</td>
<td>R</td>
<td>Renal failure, disseminated intravascular coagulation</td>
</tr>
<tr>
<td>11</td>
<td>48, M</td>
<td>Yes</td>
<td>4</td>
<td>ACV</td>
<td>15</td>
<td>14</td>
<td></td>
<td>R</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>39, F</td>
<td>Yes</td>
<td>2</td>
<td>ACV</td>
<td>6</td>
<td>13</td>
<td>0</td>
<td>R</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>31, M</td>
<td>Yes</td>
<td>3</td>
<td>ACV</td>
<td>35</td>
<td>30</td>
<td></td>
<td>R</td>
<td></td>
</tr>
</tbody>
</table>

*Minus sign indicates that respiratory symptoms preceded rash.

IPPV—intermittent positive pressure ventilation; ARA-A—vidarabine; ACV—acyclovir; R—recovered; D—died.

two years earlier in patient 1; when he developed chickenpox he had mild sarcoidosis not requiring treatment. Patient 2 had mild multiple sclerosis, and patient 8 was a chronic carrier of hepatitis B virus positive for "e" antigen but with normal liver function; neither was receiving immunosuppressive drugs. Five patients were not of British origin—Nos 1 (Jamaican), 6 (Sri Lankan), 4 and 12 (Indian), and 13 (Anglo-Indian). Eleven patients smoked, and the mean cigarette consumption was 20 a day.

**RADILOGIC FINDINGS**

All patients had radiographic abnormalities on admission to hospital and these were greater than would have been predicted from physical examination of the chest. The most consistent feature was pulmonary nodules 2–10 mm in diameter, of soft tissue density. The initial pattern of diffuse fine nodular shadowing progressed with increasing size of the nodules to coalescence and areas of consolidation (figure). The maximum radiographic changes did not correlate well with the severity of the illness. Most patients showed extensive lung disease at some stage with relative apical sparing. Basal sparing was seen less commonly, and areas of consolidation seemed to be equally common in all lobes. Six patients had a pleural effusion, usually transiently. In five this was unilateral (four left sided) and in one (patient 8) bilateral.

**BIOCHEMICAL FINDINGS**

Ten patients were hyponatraemic on admission, including the three who died (mean plasma sodium concentration 131, range 125–134 mmol/l (normal 135–145 mmol/l)).

**Patient 7:** Radiograph taken on admission to hospital showing widespread nodular shadowing up to 10 mm in diameter; there is confluent consolidation in the right lower zone and a left pleural effusion, and the hilar markings are obscured bilaterally.

**BACTERIOLOGICAL FINDINGS**

Secondary bacterial infection may have occurred in six patients. *Staphylococcus aureus* was isolated from sputum in one case; from the tip of a venous canula in another; and from skin swabs, sputum, blood cultures, and the tip of a venous canula in a third. *Staphylococcus epidermidis* was grown from blood cultures in two patients, one of whom (No 11) also had *Aspergillus* sp in blood and sputum. *Haemophilus influenzae* was isolated from the sputum of the remaining patient.
Lung Function
Respiratory function tests had been performed fortuitously in patients 1, 7, and 8 before the chickenpox pneumonia. After their illness these patients showed a reduction in carbon monoxide transfer factor, which gradually returned towards normal over several months.

Treatment and Outcome
Ten patients received an antiviral drug 2–7 days after onset of the rash, and 0–4 days after the onset of respiratory symptoms (table). One patient (No 1) received vidarabine 600 mg daily for seven days. The other nine received acyclovir 10 mg/kg body mass eight hours intravenously with a reduced dose where there was renal impairment. Patient No 3 died on the second day and No 6 on the third day after starting acyclovir treatment; the remaining patients received a five day course. The three patients who died had received acyclovir on days 5, 5, and 7 of the rash.

Discussion
There have been no controlled trials of antiviral agents in chickenpox pneumonia. The choice of drug relies therefore on case reports of adults with chickenpox pneumonia12–18 and on trials of treatment for cutaneous or visceral varicella in immunocompromised patients.19,20 Claims for efficacy in varicella pneumonia have been made for transfer factor,21 α interferon,15 vidarabine,12,16 and acyclovir.13,17,18 Acyclovir, the drug of choice in other serious varicella-zoster virus infections, may be ineffective once visceral dissemination has occurred.20 Steroids are contraindicated11 except in cases of acute adrenal failure.22 The cases reported before antiviral agents were available clearly document the swift recovery of some patients. Thus single case reports of rapid improvement are not necessarily an indication of drug efficacy. Our experience suggests little departure from the natural history of this condition, possibly because treatment was started too late. Our three patients who died had not received an antiviral drug until at least five days after the onset of the rash (table), possibly because the cause of the respiratory symptoms was not recognised immediately.

The mortality rate for varicella pneumonia has been estimated at 10–30%,4 although the incidental finding of calcification typical of previous varicella pneumonia in adult chest radiographs suggests that many cases may be unrecognised. Mortality statistics for England and Wales record around 19 deaths from chickenpox each year, a figure that remained fairly constant from 1967 to 1985,23 the period when antiviral drugs were being introduced. Controlled trials in chickenpox pneumonia are difficult in view of the rarity of the condition, but a controlled trial of treatment of adults with chickenpox, using high dose oral acyclovir (800 mg five times a day), could provide valuable information. Alternatively, all adults who develop chickenpox could have an early chest radiograph and any abnormality could be taken as an indication for starting antiviral treatment. Zoster immune globulin is effective in preventing or ameliorating chickenpox in susceptible children24,25 but it is in short supply.25 The development of monoclonal antivaricella globulin26 allows the production of large quantities of material, which could also be subjected to clinical trial.

Prevention might be a better approach, and a live attenuated vaccine was developed in Japan in 1974.27 Despite early controversy,28,29 assessment of the vaccine has shown it to be safe and effective.30 It would be difficult, however, to identify susceptible adults at an acceptable cost.

We cannot explain our cluster of cases in 1985. Infectious diseases units in other parts of the country did not report a similar increase, although one unit reported a "cluster" during 1984. Neither chickenpox nor chickenpox pneumonia is a notifiable disease, but the prevalence of chickenpox as estimated by the Royal College of General Practitioners was not unusually high (Public Health Laboratory Service Communicable Disease Report 86/06, unpublished) and schools in our locality did not report an increased number of infections.

Smoking may be a risk factor for the development of pneumonia18; of our two non-smokers, one had received a bone marrow transplant and the other (patient 10) had the mildest disease. Mean cigarette consumption was 26 a day in patients who needed intermittent positive pressure ventilation, compared with 18 a day in those who did not. Smoking renders human alveolar macrophages more susceptible to infection by herpes viruses,31 and this may have pathogenetic significance.

Studies of respiratory function abnormalities during and after chickenpox pneumonia have shown a reduction in carbon monoxide transfer coefficient (Kco) and steady state carbon monoxide diffusing capacity or transfer factor (Tlco), which may persist for years after the illness.32 Subclinical chickenpox pneumonia may also lead to a fall in Kco in smokers despite a normal chest radiograph.18

Regular samples should be taken of skin flora, blood, sputum, and urine for culture to identify secondary infections. The isolation of Staphylococcus epidermidis in blood cultures may be due to contamination, and isolation of Haemophilus influenzae and Staphylococcus aureus from sputum may be due to colonisation rather than infection. These organisms
may become invasive through the inflamed skin, however, or via intravenous cannulas, endotracheal tubes, or urinary catheters.

The severity of chickenpox in adults may have been underestimated recently and there is a strong case for a reassessment of the strategy for antiviral treatment in these patients. Probably the best approach would be a trial of high dose oral acyclovir treatment in adults who develop chickenpox.

References


Davidson, Lynn, Savage, Wansbrough-Jones

Chickenpox pneumonia: experience with antiviral treatment.
R N Davidson, W Lynn, P Savage and M H Wansbrough-Jones

Thorax 1988 43: 627-630
doi: 10.1136/thx.43.8.627

Updated information and services can be found at:
http://thorax.bmj.com/content/43/8/627

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/